Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

hiPSCmore

Financiado

Cerrado

Instrumented human stem cells to see more during high throughput screening in dr...

Instrumented human stem cells to see more during high throughput screening in drugInstrumented human stem cells to see more during high throughput screening in drug discovery and regenerativ "In hiPSCmore (read hiP-See-More), my team and I will engineer fluorescent sensors in the DNA of human induced pluripotent stem cells (hiPSC) so we can See More during high-throughput imaging screenings (imHTS) for drug discovery... ver más

31/10/2025

UNIPV

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PAVIA No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIPV

100.00K€ | Lider

DAY ONE

50.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STEMBANCC Stem cells for Biological Assays of Novel drugs and prediCti... 55M€ Cerrado

DROPTECH Hanging Drop based automated and parallelized cell technolog... 5M€ Cerrado

STEMBANCC Stem cells for Biological Assays of Novel drugs and prediCti... 55M€ Cerrado

UltraRamanomics High Content Microanalytical Ramanomics for Ultraquantitativ... 213K€ Cerrado

DISEASEAVATARS Modeling Disease through Cell Reprogramming a Translational... 2M€ Cerrado

CENSUS Cell Based Models for Neurodegeneration Study and Use in Scr... 3M€ Cerrado

Duración del proyecto: 20 meses Fecha Inicio: 2024-02-29
Fecha Fin: 2025-10-31

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PAVIA No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "In hiPSCmore (read hiP-See-More), my team and I will engineer fluorescent sensors in the DNA of human induced pluripotent stem cells (hiPSC) so we can See More during high-throughput imaging screenings (imHTS) for drug discovery and regenerative medicine. Since hiPSCs can differentiate in most cell types in the human body, they are the ideal cell source for more predictively screening therapies. Yet, hiPSCs are expensive to maintain and require external reagents to visualize pathophysiological changes, which adds to the screening cost and complexity. In fact, the major hurdle in adopting hiPSCs for imHTS has been the price increase from <0.10 $/data point to 2+ $/data point. In the context of our ERC Stg, we genetically encoded fluorescent sensors for cell structure, function, and cell cycle progression directly into hiPSCs for in-vitro modeling of heart development. With those sensors, we can visualize pathophysiological changes through reagents provided by the cells themselves. Thus, the more experiments we conduct, the cheaper they become. We believe this is the strategy to bring hiPSCs into imHTS, where testing millions of compounds vanishes an experiment's marginal cost. Like software. To explore this opportunity, we envision three main objectives. 1. Technology feasibility. We will scale up the production of our SeeMore hiPSCs and validate their cost-effectiveness in drug screening and regenerative medicine applications. 2. Business feasibility. We will analyze market dynamics and customer preferences in the drug screening and regenerative markets to define the most efficient go-to-market strategy. 3. Executive management. We will work with stakeholders in our advisory board to delineate IPR, business strategy, and future fundraising opportunities for a SeeMore spin-off company. Through these activities, the SeeMore spin-off will incorporate the right mix of tech development and business savvy in its own DNA, so it can ""seize more"" of the HTS market."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores